The TOBI PODHALER delivery system uses the PULMOSPHERE Technology, delivering up to 60% of active drug1
- Tobramycin inhalation powder is delivered to both the central and peripheral airways1
- Low interparticle cohesive forces and smaller particle size allow for the necessary dispersibility during inhalation1
- TOBI PODHALER is the first and only FDA-approved dry powder inhaled antibiotic for Pseudomonas aeruginosa — no nebulizer required
Characteristics of PULMOSPHERE powder particles1
- Low in density
- Light and porous hollow particle
- Particle size: median geometric diameter is 1.7-2.7 µm
- Minimal effort is required to disperse the particles*
- Low particle-to-particle cohesion supporting dispersibility
- Lung deposition to both central and peripheral airways
- PULMOSPHERE Technology enables rapid drug release using a device that requires little additional energy1
Watch a video on PULMOSPHERE Technology
*The lung deposition fraction of PULMOSPHERE particles was evaluated in healthy volunteers by using gamma scintigraphic images.1
REFERENCE
- Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PULMOSPHERE® Technology. J Aerosol Med Pulm Drug Deliv. 2011;24(4):175-182. doi:10.1089/jamp.2010.0855.